Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference
Rhea-AI Summary
Arcutis (Nasdaq: ARQT) announced management will present at the TD Cowen 46th Annual Health Care Conference in Boston, March 2-4, 2026. The company will host a Fireside Chat on March 2, 2026 at 1:50 p.m. ET.
The live webcast is available via the company Events page and a replay will remain accessible on the Arcutis website for 180 days following the conference.
Positive
- None.
Negative
- None.
News Market Reaction – ARQT
On the day this news was published, ARQT declined 8.19%, reflecting a notable negative market reaction. Argus tracked a trough of -2.9% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $299M from the company's valuation, bringing the market cap to $3.36B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ARQT is up 5.78% while peers show mixed moves: TARS (+3.78%), AGIO (+0.54%), IRON (+0.61%), TVTX (+1.26%), and APGE (-2.57%). This pattern points to a stock-specific reaction rather than a unified biotech or dermatology move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 25 | Earnings and guidance | Positive | +0.1% | Profitable Q4 2025, strong ZORYVE revenue growth, raised 2026 sales guidance. |
| Feb 24 | Awareness campaign | Positive | +2.5% | Max Homa joins seborrheic dermatitis campaign highlighting ZORYVE foam benefits. |
| Feb 05 | Inducement grants | Neutral | +4.8% | Equity inducement RSU grants to new hires under 2022 Inducement Plan. |
| Feb 02 | Clinical trial update | Positive | +0.8% | Positive topline INTEGUMENT-INFANT Phase 2 results for ZORYVE cream 0.05%. |
| Jan 26 | Commercial strategy | Positive | +0.5% | Termination of Kowa promotion with Arcutis retaining promotion and guidance unchanged. |
Recent company news and earnings have consistently coincided with modest positive price reactions, suggesting the market has generally rewarded Arcutis updates.
Over the last month, Arcutis reported positive Phase 2 data for ZORYVE cream in infants, mutually ended its Kowa promotion agreement while maintaining 2026 sales guidance, and posted strong Q4 and full-year 2025 results with profitability and higher 2026 revenue guidance. Additional news included a disease-awareness campaign with Max Homa and inducement equity grants. Today’s conference appearance fits into an active communication cadence focused on commercial traction, clinical expansion, and investor visibility.
Regulatory & Risk Context
An effective S-3ASR shelf filed on 2026-02-25 allows Arcutis to register multiple securities, including common and preferred stock, debt, warrants, purchase contracts, and units, and enables selling securityholders to resell shares. The company notes it will not receive proceeds from selling securityholders’ resales, and there has been no usage reported to date.
Market Pulse Summary
The stock moved -8.2% in the session following this news. A negative reaction despite neutral conference news would fit a scenario where investors reassessed recent gains after strong Q4 earnings, guidance increases, and an effective S-3ASR shelf filing. The company has seen a string of positive updates, and insider sales disclosed in early February might weigh on sentiment. In such a context, even routine conference participation could coincide with profit-taking rather than serving as a fresh upside catalyst.
AI-generated analysis. Not financial advice.
WESTLAKE VILLAGE, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will present at the TD Cowen 46th Annual Health Care Conference, taking place March 2-4, 2026, in Boston.
Details for the Company’s participation are as follows:
Fireside Chat: Monday, March 2, 2026 at 1:50 p.m. ET
The webcast for this conference may be accessed via the “Events” section of the Company’s website. A replay of the webcast will be available on the Arcutis website for 180 days following the conference.
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis’ unique dermatology development platform, coupled with our dermatology expertise allows us to develop differentiated therapies against biologically validated targets, and has produced a robust pipeline for a range of inflammatory dermatological conditions. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on The Company’s current beliefs and expectations. These statements are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2026, as well as any subsequent filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com
Investors
Brian Schoelkopf, Head of Investor Relations
ir@arcutis.com
FAQ
What time is Arcutis (ARQT) presenting at TD Cowen’s 46th Annual Health Care Conference?
How can investors watch the Arcutis (ARQT) webcast for the TD Cowen conference?
Will a replay of Arcutis (ARQT) presentation be available after the TD Cowen conference?
When does the TD Cowen 46th Annual Health Care Conference take place for Arcutis (ARQT)?
Where will Arcutis (ARQT) post conference materials or investor access details for the TD Cowen event?
